Canada has become the first country among the Group of Seven major economies to approve a generic version of Ozempic, the blockbuster weight-loss and diabetes drug, with lower-cost alternatives beginning to roll out in pharmacies across the country this month. The development has drawn significant attention in the United States, where patients continue to pay far higher prices for the same medication.
The approval by Health Canada marks a milestone in the global effort to make GLP-1 receptor agonists — the class of drugs that includes semaglutide, the active ingredient in Ozempic and Wegovy — accessible to a broader population. The drugs have become among the most sought-after medications in the world due to their effectiveness in treating type 2 diabetes and promoting significant weight loss.
Why the US Has Fallen Behind
In the United States, Ozempic and its weight-loss counterpart Wegovy remain exclusively available as brand-name drugs manufactured by Novo Nordisk. The company holds patents that have shielded the medication from generic competition, and the US Food and Drug Administration has not yet approved any biosimilar or generic semaglutide products for the market.
The contrast with Canada underscores the different regulatory timelines and pharmaceutical pricing systems at play in the two neighbouring countries. Canadian health authorities moved more quickly to approve generic alternatives once core patents expired or were successfully challenged, while the US approval process and ongoing patent litigation have kept lower-cost options out of American pharmacies.
For US patients without comprehensive insurance coverage, a monthly supply of Ozempic can cost upwards of $900. In Canada, generic versions are expected to be significantly cheaper, making treatment accessible to many more patients managing diabetes or obesity.
A Growing Demand Crisis
Demand for semaglutide drugs has surged globally since their weight-loss benefits became widely known. Shortages have been reported in multiple countries, and the high cost has placed the drugs out of reach for many patients who could medically benefit from them. Public health advocates have argued that broader access to affordable versions is essential to addressing the global obesity epidemic.
“This is a public health issue,” said one Canadian pharmacist involved in the rollout. “When a drug is this effective at treating conditions that affect millions of people, ensuring it’s affordable is not optional — it’s necessary.”
What This Means for Patients
For Canadians, the rollout of generic semaglutide represents immediate relief for patients who have been managing diabetes or struggling to access weight-loss treatment due to cost. Provinces are expected to consider including the generics on their publicly funded drug formularies, which could extend coverage to millions of additional patients.
In the US, pressure is mounting on lawmakers and regulators to accelerate the approval of biosimilar alternatives and explore legislative solutions to bring down drug prices. Several pharmaceutical companies have filed applications with the FDA for generic or biosimilar semaglutide products, but approvals could still be years away.
For now, Canada’s move sets a precedent that other nations — and eventually the United States — are likely to follow.
